February 16, 2005 -- In a trading day that saw biotech lower during the entire session, the Centient Biotech 200™ lost 19 points to close at 3363.99, a drop of .58%. The results in the broad market were mixed, with the NYSE Composite higher by a very small .04%, while Nasdaq was lower by an almost equally small .09%. Eyetech Pharma slipped after announcing 2005 sales/profits goals, Protein Design Labs sank after successfully placing $250 million worth of converts so it can buy ESP Pharma, Pfizer slid while investors await the results of the FDA hearing on COX-2 inhibitors, Neurocrine Bioscience announced a successful Phase III trial for its insomnia drug, Dendreon climbed on no news, and Millenium moved up after the Wall Street Journal said the company could be a takeover target. We give details...
